| Jun 26 |
IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial
|
| Jun 25 |
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer
|
| Jun 24 |
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors
|
| Jun 18 |
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'
|
| Jun 18 |
Investors in IDEAYA Biosciences (NASDAQ:IDYA) have seen impressive returns of 277% over the past five years
|
| Jun 3 |
IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study
|
| May 29 |
IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events
|
| May 28 |
IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development
|
| May 23 |
IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma
|
| May 8 |
IDEAYA Biosciences First Quarter 2024 Earnings: US$0.53 loss per share (vs US$0.49 loss in 1Q 2023)
|
